◼ Archived
Business
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
1 trends tracked about this subject — the full history, oldest to newest below.
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.